Search the Newsreel

Can Neogen (NEOG) Justify Its Valuation On Earnings And Fiscal 2027 Guidance?

Neogen Chemicals raises FY27 revenue guidance to ₹950-1,050 crore

Neogen (NASDAQ:NEOG) Posts Earnings Results, Beats Expectations By $0.04 EPS

Neogen (NASDAQ:NEOG) reported strong quarterly earnings, beating analyst expectations with an EPS of $0.09 against a consensus of $0.05 and revenue of $225.3 million compared to estimates of $212.35 million. Despite flat year-over-year revenue, the company provided an optimistic fiscal 2027 outlook, projecting revenues …

Neogen (NEOG) Stock Climbs As Margin Repair Counters Lingering Losses

Neogen (NEOG) stock climbed after the company reported fourth-quarter earnings showing significant margin repair, with adjusted EBITDA margins reaching over 20%. While the company still reported a net loss of US$11.3 million, this was a material reduction from the previous year, and revenue remained …

Neogen Corporation $NEOG Position Boosted by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP significantly increased its stake in Neogen Corporation by 23.4% in the first quarter, now holding 9.13 million shares. This comes as Neogen exceeded fiscal fourth-quarter earnings and revenue expectations, and provided an above-consensus fiscal 2027 outlook, despite flat year-over-year revenue …

Neogen Corporation 2026 Q4 - Results - Earnings Call Presentation (NASDAQ:NEOG) 2026-07-31

Neogen (NASDAQ:NEOG) Hits New 12-Month High After Earnings Beat

Neogen (NASDAQ:NEOG) shares surged to a new 52-week high after the company reported fiscal Q4 earnings of $0.09 per share, beating the consensus estimate of $0.05, and revenue of $225.3 million, exceeding estimates of $212.35 million. Management also provided an optimistic fiscal 2027 outlook, …

BlackRock (NEO holder) discloses 20.4M-share NeoGenomics stake in latest update

BlackRock, Inc. has filed an amended beneficial ownership report revealing a 15.6% stake in NeoGenomics, Inc., totaling 20,358,331 shares. Of these, BlackRock holds sole voting power over 19,688,877 shares and sole dispositive power over all 20,358,331 shares. The filing also notes that the iShares …

Neogen posts strongest food safety unit growth since 2023 in Q4

Neogen Corp. reported its strongest food safety unit growth in three years during Q4 fiscal 2026, with core food safety revenue growing 5.8%, driven by gains in pathogen testing, culture media, and bacterial sanitation products. Despite this, overall company revenue remained flat and the …

Neogen Corp (NEOG) (Q4 2026) Earnings Call Highlights: Strong Revenue Growth Amidst FX ...

Neogen Corporation stock hits 52-week high at 11.45 USD

Neogen Corporation (NEOG) reached a new 52-week high of $11.45, with its stock currently trading at $11.46. The food safety company has a market capitalization of approximately $2.48 billion and has seen a 143.87% increase over the past year. Despite strong performance and better-than-expected …

First Trust entities disclose 10.1M-share NeoGenomics (NEO) position in 13G

First Trust Portfolios L.P., First Trust Advisors L.P., and The Charger Corporation have jointly filed a Schedule 13G, disclosing beneficial ownership of 10,113,261 shares of NeoGenomics (NEo), which represents 7.77% of the class. First Trust Advisors L.P. and The Charger Corporation hold shared voting …

Neogen (NASDAQ:NEOG) Shares Gap Up - What's Next?

Neogen (NASDAQ: NEOG) shares gapped up by 13.5% prior to trading, opening at $10.50 after closing at $9.40, with trading volume reaching 323,123 shares. The company has a consensus "Hold" rating and a $10.67 price target from analysts, despite mixed sentiment. Institutional ownership is …

Earnings call transcript: Neogen tops Q4 2026 estimates as shares jump 10%

Neogen Corporation reported stronger-than-expected fiscal fourth-quarter results for 2026, surpassing Wall Street estimates for both earnings and revenue, which led to a 10.43% jump in premarket shares. The company highlighted improved core growth across its food safety and animal safety segments, the highest food …

Neogen Q4 FY26 slides: food safety growth hits 3-year high

Neogen Corporation reported its strongest quarterly performance since its 2023 3M food safety acquisition, with core revenue growing 4.3% and food safety sales increasing by 5.8%, a three-year high. The company outlined a strategic shift towards sustainable growth through enhanced commercial operations, a 50% …

Neogen Food Safety Core Growth Hits 5.8%, Highest Since FY23

Neogen Corporation reported Q4 FY26 revenue of $225.3 million, with Food Safety core growth at 5.8%, the highest since FY23. The company also provided FY27 guidance, projecting revenues between $880 million and $885 million, and adjusted EBITDA of $180 million to $182 million. Neogen …

Neogen (NEOG) Beats Q4 Earnings and Revenue Estimates

Neogen (NEOG) reported Q4 earnings of $0.09 per share, significantly exceeding the Zacks Consensus Estimate of $0.05 per share, and also surpassed revenue estimates with $225.3 million. The company has consistently beaten revenue estimates over the last four quarters and has outperformed the S&P …

Neogen (NEOG) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Neogen (NEOG) Earnings Date and Reports 2026

Neogen: Fiscal Q4 Earnings Snapshot

Neogen Corp. reported a fiscal fourth-quarter loss of $11.3 million, or 5 cents per share, which beat Wall Street expectations after adjustments. The medical testing kit maker posted revenue of $225.3 million for the quarter, also exceeding forecasts. For the full year, Neogen reported …

NeoGenomics, Inc. Stock 12‑Month Price Target Raised to $19.72, Implies 47% Upside

Analyst estimates have led to an increased average 12-month price target for NeoGenomics, Inc. (NEO) stock, rising from $16.78 to $19.72, with a range of $16 to $35 per share. This updated target suggests a potential upside of approximately 47% from its closing price …

NeoGenomics (NEO) Stock Rallies As Profit Returns And Margins Improve

NeoGenomics (NEO) stock rallied by 14% after reporting a swing from a Q1 loss to a modest Q2 profit, driven by improved margins and increased average price per test. While clinical revenue and NGS growth are strong, concerns remain regarding the decline in pharma …

Needham raises Neogenomics stock price target on strong Q2 results

Needham has increased its price target for Neogenomics Inc. (NASDAQ:NEO) to $19.00 from $15.00, maintaining a Buy rating, following strong second-quarter 2026 results. The company surpassed revenue and EBITDA consensus estimates, leading management to raise full-year guidance and indicating a potential return to profitability …

Neogenomics stock hits 52-week high at 15.61 USD

NeoGenomics Inc. (NEO) stock reached a 52-week high of $15.61 USD, representing a 162.75% increase over the past year. Despite trading above its Fair Value, analysts are optimistic about the company turning profitable this year. This surge follows strong second-quarter 2026 earnings, where NeoGenomics …

NeoGenomics Reports Second Quarter 2026 Results

NeoGenomics, Inc. announced its second-quarter 2026 results, showing an 11% year-over-year increase in total revenue to $202 million, with robust clinical services revenue growth of 14% driven by a 26% increase in NGS revenue. The company reported a GAAP net income of $2 million …

Gamco Investors INC. ET AL Boosts Stock Holdings in NeoGenomics, Inc. $NEO

Gamco Investors INC. ET AL significantly increased its stake in NeoGenomics, Inc. by 525% in the first quarter, now holding 100,000 shares valued at $742,000. This move comes as NeoGenomics reported better-than-expected Q2 earnings and raised its fiscal 2026 revenue guidance, despite ongoing concerns …

Neogen Chemicals Limited Just Beat EPS By 69%: Here's What Analysts Think Will Happen Next

NeoGenomics (NASDAQ:NEO) Hits New 1-Year High After Better-Than-Expected Earnings

Why NeoGenomics (NEO) Stock Is Up Today

NeoGenomics Inc (NEO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Raised ...

NeoGenomics Inc (NEO) reported strong Q2 2026 results with an 11% year-over-year revenue growth to $201.7 million, driven by robust clinical and Next-Generation Sequencing (NGS) performance. The company raised its full-year 2026 revenue guidance to $802 million to $806 million and adjusted EBITDA guidance …

NeoGenomics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NEO) 2026-07-28

This article announces that NeoGenomics, Inc. published its Q2 2026 earnings call presentation. The company reported an EPS of $0.05, beating estimates by $0.02, and revenue of $201.66M, surpassing expectations by $4.67M and representing an 11.21% year-over-year increase. The presentation is related to their …

NeoGenomics anticipates $802M-$806M 2026 revenue as it targets mid-20% NGS growth and adjusts pharma expectations

Earnings Call Insights: NeoGenomics (NEO) Q2 2026 MANAGEMENT VIEW * "We're raising guidance because of these results as well as the underlying clinical strength we're seeing in the back half of this year." (CEO Anthony Zook) * "Total revenue in the quarter was $201.7 …

NeoGenomics (NASDAQ:NEO) Posts Earnings Results, Beats Expectations By $0.02 EPS

NeoGenomics (NASDAQ:NEO) reported quarterly earnings that surpassed analyst expectations, with an EPS of $0.05 against an estimated $0.03, and revenue of $201.66 million, exceeding the $196.93 million estimate. Despite the positive earnings surprise, the company posted a negative net margin and return on equity. …

Earnings call transcript: NeoGenomics tops Q2 2026 estimates and lifts outlook

NeoGenomics Inc. reported strong second-quarter 2026 earnings, surpassing Wall Street expectations for both profit and sales, driven by robust clinical and next-generation sequencing (NGS) business growth. The company raised its full-year 2026 revenue and adjusted EBITDA guidance, despite continued weakness in its non-clinical pharma …

Resultados trimestrales: NeoGenomics supera las previsiones con un beneficio por acción ajustado de 0,05 USD en el segundo trimestre

NeoGenomics Releases Q2 2026 Financial Results

NeoGenomics, Inc. reported strong Q2 2026 financial results, with adjusted EPS of $0.05, significantly beating analyst estimates, and revenue of $201.7M, surpassing consensus. The company saw an 11.2% increase in revenue year-over-year, primarily driven by its clinical services segment. Management provided full-year adjusted EPS …